Eyes on 3D‐Current 3D Biomimetic Disease Concept Models and Potential Applications in Age‐Related Macular Degeneration
Source abstract
Abstract
Abstract Three‐dimensional cellular models that mimic disease are being increasingly investigated and have opened an exciting new research area into understanding pathomechanisms. The advantage of 3D in vitro disease models is that they allow systematic and in‐depth studies of physiological and pathophysiological processes with less costs and ethical concerns that have arisen with animal models. The purpose of the 3D approach is to allow crosstalk between cells and microenvironment, and with cues from the microenvironment, cells can assemble their niche similar to in vivo conditions. The use of 3D models for mimicking disease processes such as cancer, osteoarthritis etc., is only emerging and allows multidisciplinary teams consisting of tissue engineers, biologist biomaterial scientists and clinicians to work closely together. While in vitro systems require rigorous testing before they can be considered as replicates of the in vivo model, major steps have been made, suggesting that they will become powerful tools for studying physiological and pathophysiological processes. This paper aims to summarize some of the existing 3D models and proposes a novel 3D model of the eye structures that are involved in the most common cause of blindness in the Western World, namely age‐related macular degeneration (AMD).
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Retinal Diseases and Treatments · Angiogenesis and VEGF in Cancer · Retinal Development and Disorders
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (90)
Show source-provided references
1. 10.1038/nature1110210.1038/nature11102 ↗
2. 10.1038/483373a10.1038/483373a ↗
3. 10.1089/ten.tea.2010.013510.1089/ten.tea.2010.0135 ↗
4. 10.1002/jps.2225710.1002/jps.22257 ↗
5. 10.1016/j.cell.2007.08.00610.1016/j.cell.2007.08.006 ↗
6. 10.1002/jcp.2183210.1002/jcp.21832 ↗
7. 10.1038/nrm185810.1038/nrm1858 ↗
8. 10.1038/nmat244110.1038/nmat2441 ↗
9. 10.1111/j.1600-0625.2011.01309.x10.1111/j.1600-0625.2011.01309.x ↗
10. Chekhonin V. P. · Curr. Cancer Drug Targets · 2012
11. 10.1159/00032000710.1159/000320007 ↗
12. Tremolada G. · Exp. Diabetes Res. · 2012
13. 10.1016/j.biomaterials.2006.09.03810.1016/j.biomaterials.2006.09.038 ↗
14. 10.1016/j.bpj.2010.11.08210.1016/j.bpj.2010.11.082 ↗
15. 10.1002/bit.2302710.1002/bit.23027 ↗
16. 10.1016/j.tibtech.2010.12.00810.1016/j.tibtech.2010.12.008 ↗
17. 10.1089/ten.teb.2009.067610.1089/ten.teb.2009.0676 ↗
18. 10.1089/ten.1995.1.15110.1089/ten.1995.1.151 ↗
19. Domansky K. · Conf. Proc. IEEE Eng. Med. Biol. Soc. · 2005 · 7 · 7490
20. 10.1002/bit.1014310.1002/bit.10143 ↗
21. 10.1089/10763270276018474510.1089/107632702760184745 ↗
22. 10.1039/B913221J10.1039/B913221J ↗
23. 10.1007/978-1-60761-984-0_910.1007/978-1-60761-984-0_9 ↗
24. 10.1016/j.biomaterials.2008.12.00910.1016/j.biomaterials.2008.12.009 ↗
25. 10.1016/j.biomaterials.2012.05.00810.1016/j.biomaterials.2012.05.008 ↗
26. 10.1152/ajpheart.01027.200210.1152/ajpheart.01027.2002 ↗
27. 10.1161/circ.102.suppl_3.III-5610.1161/circ.102.suppl_3.III-56 ↗
28. 10.1007/s12265-007-9005-x10.1007/s12265-007-9005-x ↗
29. 10.1016/S0140-6736(06)68438-910.1016/S0140-6736(06)68438-9 ↗
30. 10.1016/S0140-6736(08)61598-610.1016/S0140-6736(08)61598-6 ↗
31. 10.1016/S0076-6879(08)02005-310.1016/S0076-6879(08)02005-3 ↗
32. 10.1002/jbm.b.3161110.1002/jbm.b.31611 ↗
33. 10.1007/978-1-59745-443-8_610.1007/978-1-59745-443-8_6 ↗
34. 10.1016/j.biomaterials.2010.12.04110.1016/j.biomaterials.2010.12.041 ↗
35. 10.1016/j.tiv.2011.02.00210.1016/j.tiv.2011.02.002 ↗
36. Leite S. B. · Toxicol Sci · 2012
37. 10.1002/(SICI)1097-0290(19990905)64:5<580::AID-BIT8>3.0.CO;2-X10.1002/(SICI)1097-0290(19990905)64:5<580::AID-BIT8>3.0.CO;2-X ↗
38. 10.1016/j.copbio.2009.10.01610.1016/j.copbio.2009.10.016 ↗
39. 10.1161/01.RES.0000196562.73231.7d10.1161/01.RES.0000196562.73231.7d ↗
40. 10.1038/nprot.2006.44810.1038/nprot.2006.448 ↗
41. 10.1371/journal.pone.002343410.1371/journal.pone.0023434 ↗
42. 10.1002/jcp.2078710.1002/jcp.20787 ↗
43. Vahidnezhad H. · Iran. Biomed. J. · 2009 · 13 · 191
44. 10.1371/journal.pone.001043110.1371/journal.pone.0010431 ↗
45. 10.1016/j.semcancer.2005.05.00510.1016/j.semcancer.2005.05.005 ↗
46. Carlson M. W. · Curr. Protoc. Cell Biol. · 2008
47. Li L. · J. Vis. Exp. · 2011
48. 10.1007/s11605-010-1283-y10.1007/s11605-010-1283-y ↗
49. 10.1016/S0065-230X(06)97010-910.1016/S0065-230X(06)97010-9 ↗
50. 10.1007/978-1-60761-984-0_1310.1007/978-1-60761-984-0_13 ↗
51. 10.1080/1042819070157319010.1080/10428190701573190 ↗
52. Wong C. · J. Vis. Exp. · 2012 · 66 · e4218
53. 10.1016/S0092-8674(00)81683-910.1016/S0092-8674(00)81683-9 ↗
54. 10.1073/pnas.89.19.906410.1073/pnas.89.19.9064 ↗
55. 10.1016/S1535-6108(02)00125-310.1016/S1535-6108(02)00125-3 ↗
56. 10.1002/(SICI)1097-0045(19990601)39:4<246::AID-PROS5>3.0.CO;2-U10.1002/(SICI)1097-0045(19990601)39:4<246::AID-PROS5>3.0.CO;2-U ↗
57. 10.1007/s11626-997-0008-310.1007/s11626-997-0008-3 ↗
58. 10.1021/mp100079510.1021/mp1000795 ↗
59. 10.1089/ten.tea.2009.059510.1089/ten.tea.2009.0595 ↗
60. 10.1016/j.biomaterials.2012.08.02010.1016/j.biomaterials.2012.08.020 ↗
61. 10.1016/j.biomaterials.2010.01.11110.1016/j.biomaterials.2010.01.111 ↗
62. Oortgiesen D. A. · J. Tissue Eng. Regen. Med. · 2012
63. 10.1111/j.1469-7580.2007.00812.x10.1111/j.1469-7580.2007.00812.x ↗
64. 10.1089/ten.tec.2011.036710.1089/ten.tec.2011.0367 ↗
65. AccessEconomics2010 http://www.amdalliance.org/user_files/documents/Global%20cost%20of%20VI_FINAL%20report.pdf.
66. 10.1016/S0039-6257(05)80092-X10.1016/S0039-6257(05)80092-X ↗
67. 10.1016/j.preteyeres.2008.11.00410.1016/j.preteyeres.2008.11.004 ↗
68. 10.1096/fasebj.14.7.83510.1096/fasebj.14.7.835 ↗
69. 10.1016/S0002-9394(02)01624-010.1016/S0002-9394(02)01624-0 ↗
70. 10.1126/science.110955710.1126/science.1109557 ↗
71. 10.1073/pnas.050153610210.1073/pnas.0501536102 ↗
72. 10.1001/archopht.119.10.141710.1001/archopht.119.10.1417 ↗
73. 10.1056/NEJMoa06265510.1056/NEJMoa062655 ↗
74. 10.1016/j.ophtha.2011.12.01610.1016/j.ophtha.2011.12.016 ↗
75. 10.1111/j.1442-9071.2011.02581.x10.1111/j.1442-9071.2011.02581.x ↗
76. 10.1016/B978-0-12-384878-9.00006-610.1016/B978-0-12-384878-9.00006-6 ↗
77. 10.1016/S0039-6257(00)00140-510.1016/S0039-6257(00)00140-5 ↗
78. 10.1038/eye.1994.5710.1038/eye.1994.57 ↗
79. 10.1016/j.biomaterials.2012.02.04010.1016/j.biomaterials.2012.02.040 ↗
80. 10.1016/j.cis.2010.10.00310.1016/j.cis.2010.10.003 ↗
81. 10.1002/jcp.2054610.1002/jcp.20546 ↗
82. Mithieux S. M. · Adv. Drug Delivery Rev. · 2012
83. 10.1016/j.preteyeres.2009.08.00310.1016/j.preteyeres.2009.08.003 ↗
84. 10.1167/iovs.04-031110.1167/iovs.04-0311 ↗
85. 10.1016/j.exer.2009.06.00510.1016/j.exer.2009.06.005 ↗
86. 10.1073/pnas.110970310810.1073/pnas.1109703108 ↗
87. Ryan S. J. · Trans. Am. Ophthalmol. Soc. · 1979 · 77 · 707
88. 10.1016/S1350-9462(02)00043-510.1016/S1350-9462(02)00043-5 ↗
89. 10.1007/s00417-003-0828-010.1007/s00417-003-0828-0 ↗
90. 10.1185/03007995.2011.60330110.1185/03007995.2011.603301 ↗